SA Asks: What are the most promising oncology companies right now?

retained text

Search fieldHome page Seeking Alpha - Power to InvestorsAbout PremiumCreate free accountSearch for Symbols, analysts, keywordsLog in

SA Asks: What are the most promising oncology companies right now?

Aug 22, 2026, 5:57 PM ETPfizer Inc. (PFE) Stock, LEGN StockIBB, XLV, PPH, JNJ, BMY, ABT, MRK, XBI, IHE, XPH, OPK, IOVA, COGT, MRNA, NUVBBy : Val Brickates Kennedy, SA News Editor

Earlier this week, shares of Moderna (MRNA) and partner Merck (MRK) rallied on positive Phase 3 results for the their mRNA-based vaccine in the treatment of melanoma.

We asked Seeking Alpha analysts Stephen Ayers, ALLKA Research, and Gen

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Quick Insights

Analysts highlighted Iovance, Nuvation Bio, Cogent Biosciences, OPKO Health, and Legend Biotech as promising oncology drug developers.

Cogent is preparing to launch bezuclastinib with sunitinib for gastrointestinal stromal tumors and systemic mastocytosis, noting its differentiated safety profile compared to Ayvakit.

Pfizer has a strong antibody-drug conjugate pipeline via Seagen acquisition, while Abbott expanded into cancer diagnostics through the Exact Sciences acquisition.

document fetched 2026-08-23 06:30 · canonical https://seekingalpha.com/news/4636045-sa-asks-what-are-the-most-promising-oncology-companies-right-now?feed_item_type=news